Registration Dossier

Administrative data

Key value for chemical safety assessment

Additional information

N,N-Dibenzylamine was tested in the Ames test according to the respective guideline (plate incorporation and preincubation methodology) in the presence and in the absence of amethbolic activation system using concentrations of up to and including 5000 µg/plate (cytotoxic) but evidence on mutagenic activity was not seen. Positive controls were functional. Therefore, N,N Dibenzylamine was considered to be non-mutagenic in the Ames test (Bayer AG 1995)


Short description of key information:
N,N-Dibenzylamine is not mutagenic in in in-vitro gene mutationstudy in bacteria (A,es test). According to ANNEX VII section 8.4 column 2 no further mutagenicity studies have to be considered.

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

No classification has to be required